[Implications for clinical decision-making of the NOAH-AFNET 6 and ARTESiA studies: what risk-benefit ratio of anticoagulation in patients with subclinical atrial fibrillation?]

G Ital Cardiol (Rome). 2024 Apr;25(4):215-219. doi: 10.1714/4244.42201.

[Article in Italian]

Authors

Giuseppe Boriani¹, Marta Mantovani¹, Chiara Birtolo¹, Ilaria Righelli¹, Luigi Gerra¹

Affiliation

¹ Cardiologia, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università degli Studi di Modena e Reggio Emilia, Policlinico di Modena, Modena.

PMID: 38526356
DOI: 10.1714/4244.42201

No abstract available

MeSH terms

Anticoagulants / adverse effects
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Clinical Decision-Making
Humans

Substances

Anticoagulants